Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Anastasios Stathis, Alexia Iasonos, John F Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018
J.F. Seymour reports receiving commercial research grants from Janssen, Celgene, Roche, and Abbvie; reports receiving speakers bureau honoraria from Abbvie and Roche; and is a consultant/advisory board member for Abbvie, Celgene, Janssen, Roche, Sunesis, and Takeda. V. Ribrag is a consultant/advisory board member for Gilead; Infinity; MSD; Bristol, Myers Squibb; Epizyme; Nanostring; Incyte; and Pharmamar. E. Zucca reports receiving speakers bureau honoraria from Gilead, and is a consultant/advisory board member for Roche, Celgene, Abbvie, and Janssen. No potential conflicts of interest were disclosed by the other authors.